Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Sagimet Biosciences Inc.NASDAQ: SGMT
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow declines year over year
Q1 FY2026 free cash flow of $8.61M (cash outflow) fell 40.8% year over year, behind the -21.7% change in trailing-twelve-month free cash flow. Sequentially, it fell 27.2% from the prior quarter. Over 3 fiscal years it compounded at +23.1% a year.
Context
- Free cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -40.8% toward the trailing-twelve-month pace of -21.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (45.65M) USD
- Year-over-year change
- -7.6%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (45.65M) | -7.6% |
| FY2024 | 2024-12-31 | (42.44M) | -78.6% |
| FY2023 | 2023-12-31 | (23.77M) | +3.0% |
| FY2022 | 2022-12-31 | (24.49M) | -12.8% |
| FY2021 | 2021-12-31 | (21.71M) | — |
Free Cash Flow vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's LTM Mar 2026 free cash flow of $39.73M is the smallest of the 11 companies compared; the peer median is $80.09M.
- Its year-over-year change of -21.7% is the 9th highest of 11, against a peer median of +7.8%.
- Over three fiscal years its annual growth of +23.1% compares with a peer median of +9.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $147.86M | +17.2% | +2.4% | — | |
| LTM Mar 2026 | $131.64M | +126.9% | +10.3% | 2294.2% | |
| LTM Mar 2026 | $129.94M | +14.0% | +108.0% | 356.1% | |
| LTM Mar 2026 | $102.38M | +1.6% | +13.6% | 5078.2% | |
| LTM Mar 2026 | $87.42M | -8.8% | — | 309.7% | |
ZURAZura Bio Limited | LTM Mar 2026 | $72.75M | +112.3% | +70.1% | — |
| LTM Mar 2026 | $58.89M | -34.5% | — | 129.9% | |
| LTM Mar 2026 | $49.91M | -7.0% | +0.5% | — | |
| LTM Mar 2026 | $45.31M | +27.4% | +9.6% | — | |
| LTM Mar 2026 | $39.84M | -29.1% | -21.3% | 56.0% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $39.73M | -21.7% | +23.1% | — |
| Peer median (excluding SGMT) | $80.09M | +7.8% | +9.9% | 332.9% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Depreciation & Amortization | 0 | 130K | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.9M | 1.88M | 4.99M | 5.29M | 6.45M |
| Change in Working Capital | (55K) | 4.21M | (978K) | (1.05M) | (1.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 120K | (907K) | 929K |
| Other Working Capital | (55K) | 4.21M | (1.1M) | (141K) | (1.98M) |
| Other Non-Cash Items | 883K | (215K) | 98K | (1.11M) | (8K) |
| Operating Cash Flow | (21.71M) | (24.49M) | (23.77M) | (42.44M) | (45.65M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (41.45M) | (19.62M) | (108.09M) | (106.86M) |
| Sales of Investments | 0 | 9.44M | 32.2M | 46.4M | 111.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (32.01M) | 12.58M | (61.68M) | 4.56M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 12K | 89.68M | 105.75M | 275K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.07M) | (85K) | (3.51M) | (931K) | 0 |
| Financing Cash Flow | 9.74M | (73K) | 86.17M | 104.82M | 275K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.97M) | (56.57M) | 74.98M | 701K | (40.82M) |
| Free Cash Flow | (21.71M) | (24.49M) | (23.77M) | (42.44M) | (45.65M) |
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.